Aseef Ahmed, DO
Glaucoma Specialist · Boston, MANPI 1649769233
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,306, more than ten times the $81 reported in 2022.
Across 129 payments — averaging $38.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$916
- Alcon$732
- Glaukos Corporation$684
- Sight Sciences, Inc.$462
- Bausch & Lomb Americas Inc.$383
- NEW World Medical,inc.$379
- plus $1K from 8 others
What the payments were for
- Food & beverage$4,996100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $916 |
| Alcon | 19 | $732 |
| Glaukos Corporation | 8 | $684 |
| Sight Sciences, Inc. | 5 | $462 |
| Bausch & Lomb Americas Inc. | 14 | $383 |
| NEW World Medical,inc. | 4 | $379 |
| Sun Pharmaceutical Industries Inc. | 18 | $371 |
| Biotissue Holdings Inc. | 6 | $304 |
| Tarsus Pharmaceuticals, Inc. | 10 | $271 |
| Rxsight Inc | 3 | $208 |
| Dompe US, Inc. | 4 | $99 |
| Oyster Point Pharma, Inc. | 4 | $87 |
| Lensar, Inc. | 1 | $54 |
| Thea Pharma Inc. | 2 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$438
- XEN GLAUCOMA TREATMENT SYSTEM$358
- Kahook Dual Blade$297
- Clearpath$297
- Ahmed Glaucoma Valve$297
- Streamline$297
- Rocklatan$269
- iDoseTR$211
- Photrexa Viscous and Photrexa$178
- DURYSTA$150
- Via360$127
- RXSIGHT CONTACT LENS$124
- RXSIGHT INJECTOR CARTRIDGE$124
- RXSIGHT INJECTOR HANDPIECE$124
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$124
- LIGHT ADJUSTABLE LENS (LAL)$124
- Rhopressa$123
- MIEBO$122
- XIIDRA$122
How this compares
Too few glaucoma specialist providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 71 | $44,744 |
| RestasisCyclosporine | 50 | $37,441 |
| RocklatanNetarsudil Mesylat/Latanoprost | 46 | $32,973 |
| RhopressaNetarsudil Mesylate | 35 | $20,473 |
| CequaCyclosporine | 21 | $15,720 |
| Alphagan PBrimonidine Tartrate | 22 | $12,677 |
| Bromfenac Sodium | 80 | $10,031 |
| XiidraLifitegrast | 12 | $9,394 |
| Prednisolone Acetate | 212 | $9,197 |
| VyzultaLatanoprostene Bunod | 16 | $6,325 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $5,441 |
| Cyclosporine | 20 | $5,290 |
| Latanoprost | 358 | $4,653 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $4,535 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 216 | $3,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $916 | $99,398155 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $383 | $15,72028 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $371 | $15,72021 claims |
| AlconSimbrinza | $732 | $5,44124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Massachusettson file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Boston
- Cynthia MattoxBoston$91K
- Sarwat SalimBoston$83K
- Michael GiovingoBoston$22K
- Michelle HuynhBoston$2K
- Courtney OndeckBoston$789
- Deidrya JacksonBoston$511
- Chandrasekharan KrishnanBoston$223
- Susan LiangTaunton$3K
- Isha IngleWorcester$2K
- Nathalie RiouxGreenfield$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.